ArticleScientific reports2019

Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson's disease.

Takuya Uehara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.